MICOT PHARMA-B (02335): The Phase II clinical trial of MT200605 for acute ischemic stroke (AIS) has been completed in China.
Maicao Pharmaceuticals-B (02335) announced that the Phase II clinical trial for its self-developed candidate drug MT200605, used to treat acute ischemic stroke, has been completed. The clinical trial has demonstrated significant and robust efficacy advantages as well as good safety profile.
MICOT PHARMA-B (02335) announced that the Phase II clinical trial of its self-developed candidate drug MT200605 for the treatment of acute ischemic stroke has been completed. The trial has demonstrated significant and robust efficacy advantages along with good safety.
Related Articles
US Stock Market Move | Kanzhun Ltd. Sponsored ADR (BZ.US) surged over 18% with Q2 revenue increasing by 14.1% year-on-year.
US Stock Market Move | The MSCI index exclusion risk strikes again, and Strategy (MSTR.US) has dropped over 4%.
MP CARDIOFLOW-B(02160) has appointed Zhang Ruinian as the company's president.
US Stock Market Move | Kanzhun Ltd. Sponsored ADR (BZ.US) surged over 18% with Q2 revenue increasing by 14.1% year-on-year.
US Stock Market Move | The MSCI index exclusion risk strikes again, and Strategy (MSTR.US) has dropped over 4%.
MP CARDIOFLOW-B(02160) has appointed Zhang Ruinian as the company's president.
RECOMMEND
